Mark & Associates, P.C. | Attorneys at Law

Live chat by Boldchat

By submitting this form I agree to the following disclaimer.

Helping People at Risk Due to Significant Asbestos Exposure

Ninth & Tenth Cases of PML in Tysabri Patients Reported

On June 19, 2009, Biogen Idec Inc. said a ninth Tysabri patient developed a potentially deadly brain infection since the drug was reintroduced to the market in 2006. The drug, which treats multiple sclerosis, was pulled from the market in 2005 following occurrences of a rare, but deadly, brain infection ...